Merck’s KEYTRUDA combo wins key EU backing for bladder cancer treatment
The decision now moves to the European Commission, with a final ruling expected by the third quarter of 2026
The decision now moves to the European Commission, with a final ruling expected by the third quarter of 2026
Clearance marks major shift beyond chemotherapy
The decision marks a key step in the centralized EU review process
SFDA nod marks company’s strategic entry into high-value specialty oncology injectables as it targets expanding stem cell transplant and haemato-oncology market in the GCC region
Approved product is therapeutically equivalent to Synthroid of AbbVie and is indicated for the treatment of congenital or acquired hypothyroidism
The approval has been secured in partnership with Yabao Pharmaceuticals, a major player in China’s paediatric medicine segment
The drug is indicated for the maintenance treatment of patients with Chronic Obstructive Pulmonary Disease (COPD)
The development comes as stroke remains one of the world’s biggest health threats
AstraZeneca highlighted the move as a major step toward earlier intervention in curable disease
Baxfendy works in a fundamentally different way from current therapies
Antiviral injection addressing CMV and HSV infections had US market sales of nearly $15 million in the last 12 months
Famotidine Injection USP is a generic version of Pepcid injection to be manufactured at its Nagpur facility for the U.S. market
The certification follows an inspection conducted by the Malta Medicines Authority between January 29, 2026, and February 3, 2026
Darolutamide Tablets, 300 mg, had an estimated market size of US$ 3,155 million in the United States
The decision marks a significant expansion for Pfizer’s once-weekly injectable therapy
The once-daily oral therapy is the first and only tyrosine kinase 2 (TYK2) inhibitor approved in the European Union for this indication, marking a significant expansion of its immunology portfolio
Approval strengthens the company’s growing international anti-infective portfolio
Fresenius Kabi's approved generic therapy addresses acute symptomatic hypocalcemia and targets a US market valued at nearly $71 million
Subscribe To Our Newsletter & Stay Updated